Every material Form 8-K HCA Healthcare filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
HCA Inc., a wholly owned subsidiary of HCA Healthcare, completed on November 5, 2026 a public offering of $6.5 billion of senior unsecured notes in seven series maturing from 2028 to 2056, fully guaranteed by HCA Healthcare. The filing does not state how the proceeds will be used, but the offering adds $6.5 billion of debt obligations for the company.
Seven series totaling $6.5 billion; the largest is $1.5 billion of 6.000% senior notes due November 15, 2036.
Fixed-rate coupons range from 5.200% to 6.500%, and $300 million of floating-rate notes mature November 3, 2028.
Underwriting agreement dated November 2, 2026 with Mizuho Securities USA LLC, Barclays Capital Inc., BofA Securities, Inc. and Wells Fargo Securities, LLC as representatives.
Holders can require repurchase at 101% of principal only upon both a qualifying ratings downgrade and a change of control.
HCA Healthcare's wholly owned subsidiary, HCA Inc., proposed a public offering of senior unsecured notes on November 2, 2026, with terms to depend on market conditions. The subsidiary also gave notice it will redeem all $1.200 billion of its 4.500% senior notes due February 2027 on December 2, 2026, conditioned on receiving offering proceeds, which may also repay commercial paper and credit facility borrowings.
Proposed offering of senior unsecured notes by HCA Inc.; maturity, interest rate and principal amount not yet set
Notice given November 2, 2026 to redeem all $1.200 billion of 4.500% senior notes due February 2027 on December 2, 2026
Net proceeds may be used for general corporate purposes, including the redemption, repaying up to $8.000 billion commercial paper program borrowings, and repaying senior unsecured credit facility borrowings
HCA Healthcare reported third quarter 2026 revenue of $19.849 billion and net income of $1.579 billion, alongside an updated full-year operating forecast in the upper half of its previously issued ranges. The company experienced an unfavorable payer mix shift due to increased uninsured volume, which negatively impacted pre-tax income by approximately $400 million.
Revenues increased 3.6 percent to $19.849 billion in the third quarter of 2026.
Net income attributable to HCA Healthcare, Inc. declined 3.9 percent to $1.579 billion.
The Board of Directors declared a quarterly cash dividend of $0.78 per share payable on December 29, 2026.
The company repurchased 7.230 million shares of its common stock at a cost of $2.970 billion during the third quarter.
HCA Healthcare reported second-quarter 2026 revenue of $20.230 billion, up 8.7%, and diluted EPS of $7.62, up 11.6%. The company lowered its 2026 guidance for net income, EPS and Adjusted EBITDA, citing a payer mix shift from uninsured volume tied to health insurance exchanges, which it estimated reduced second-quarter income before income taxes by approximately $400 million.
Q2 2026 revenue was $20.230 billion, up 8.7% from $18.605 billion; diluted EPS was $7.62 versus $6.83 a year earlier.
Revised 2026 diluted EPS guidance is $28.70 to $30.50, down from $29.10 to $31.50; net income guidance is $6.300 to $6.700 billion, down from $6.495 to $7.035 billion.
The exchange-related payer mix shift had an unfavorable impact of approximately $400 million on Q2 income before income taxes, partly offset by about $400 million of incremental Medicaid Supplemental Payment Program benefit.
The Board declared a quarterly cash dividend of $0.78 per share, payable September 30, 2026 to holders of record on September 16, 2026.
HCA Healthcare preliminarily reported second-quarter 2026 revenues of $20.230 billion and net income of $1.699 billion, or $7.62 per diluted share, both up from the year-earlier quarter. The company also lowered its 2026 net income and EPS guidance, citing a payer mix shift from health insurance exchange coverage losses, which shareholders should weigh against the stronger quarter. The preliminary figures are unaudited and subject to final quarterly closing procedures.
Q2 2026 revenues about $20.230 billion vs. $18.605 billion in Q2 2025; net income $1.699 billion ($7.62 per diluted share) vs. $1.653 billion ($6.83).
2026 diluted EPS guidance lowered to $28.70 to $30.50 from $29.10 to $31.50; net income guidance lowered to $6.300 billion to $6.700 billion from $6.495 billion to $7.035 billion.
Q2 unfavorable payer mix impact from exchange coverage losses estimated at about $400 million, partly offset by about $400 million of incremental Medicaid Supplemental Payment Program benefit.
Second-quarter earnings call scheduled for Friday, July 24, 2026, at 9:00 a.m. Central Time.
HCA Healthcare said Dr. Michael Cuffe, Executive Vice President and Chief Clinical Officer, will step down from that role effective August 31, 2026, under an agreement reached June 15, 2026. He will then serve in a transitional role until February 2027. The filing does not name a successor, and the change involves a senior clinical executive rather than the chief executive or chief financial officer.
Dr. Michael Cuffe steps down as Executive Vice President and Chief Clinical Officer effective August 31, 2026
Transitional role with the company continues until February 2027
Eligible for benefits under the company's executive severance policy and applicable incentive plans
Agreement reached June 15, 2026; 8-K dated June 18, 2026
HCA Inc., a wholly owned subsidiary of HCA Healthcare, completed a public offering of $3 billion of senior unsecured notes on April 30, 2026. The notes are guaranteed by HCA Healthcare and are registered under a shelf registration statement, so the filing adds $3 billion of debt for the company group.
Three tranches: $1 billion of 4.700% notes due May 15, 2031; $750 million of 5.000% notes due May 15, 2033; and $1.25 billion of 5.300% notes due May 15, 2036
Interest is payable semi-annually on May 15 and November 15, starting November 15, 2026
Notes are fully and unconditionally guaranteed by HCA Healthcare, Inc. on a senior unsecured basis
Underwriting agreement dated April 27, 2026, with Citigroup, Barclays, BofA Securities and J.P. Morgan as representatives of the underwriters
HCA Healthcare reported first-quarter 2026 revenues of $19.109 billion, up 4.3%, and diluted earnings per share of $7.15, up 10.9% from $6.45 a year earlier. The company reaffirmed its 2026 guidance and declared a quarterly dividend of $0.78 per share, payable June 30, 2026.
Revenues rose 4.3% to $19.109 billion; net income attributable to HCA Healthcare was $1.620 billion, up 0.6%.
Adjusted EBITDA rose 1.9% to $3.802 billion, though its margin fell to 19.9% from 20.4%.
Respiratory-related admissions fell 42%, and a January winter storm hurt volumes; Medicaid supplemental programs not in initial guidance offset much of the impact.
Guidance reaffirmed for 2026, including diluted EPS of $29.10 to $31.50; the company repurchased 3.157 million shares for $1.571 billion in the quarter.
HCA Healthcare's Compensation Committee adopted a 2026 Executive Officer Performance Excellence Program on February 24, 2026, setting cash bonus targets for named executives, including 175% of base salary for CEO Samuel N. Hazen. Separately, director Robert J. Dennis said he will retire from the board at the April 23, 2026 annual meeting. The filing does not report financial results, so the bonus plan's effect on shareholders depends on the performance targets, which are defined in the plan document.
Awards are weighted 80% on EBITDA targets and 20% on quality metrics, paid solely in cash.
Target 2026 awards: 175% of base salary for CEO Samuel N. Hazen; 125% for CFO Michael A. Marks and COO Jon M. Foster; 100% for Michael R. McAlevey and Michael S. Cuffe, M.D.
Robert J. Dennis, who informed the company on February 20, 2026, will retire from the board effective April 23, 2026.
HCA Healthcare reported fourth-quarter 2025 revenue of $19.513 billion, up 6.7 percent, and diluted EPS of $8.14, up 44.6 percent from a year earlier, when results included a $0.59 per share facility loss. The company also issued 2026 guidance of $29.10 to $31.50 diluted EPS and authorized an additional $10 billion share repurchase program, with a $0.78 quarterly dividend declared.
Q4 2025 net income attributable to HCA was $1.878 billion, up 30.6 percent; adjusted diluted EPS was $8.01, up 28.8 percent.
Full-year 2025 revenue was $75.600 billion and diluted EPS was $28.33, compared with $22.00 in 2024.
2026 guidance: revenue $76.500 to $80.000 billion; net income $6.495 to $7.035 billion; adjusted EBITDA $15.550 to $16.450 billion.
Board authorized up to $10 billion in additional buybacks and declared a $0.78 dividend payable March 31, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every HCA Healthcare filing is on SEC EDGAR ↗. 8-K briefs of other companies →